Brief: Cingulate Provides 2022 Clinical Plan For CTX-1301

Cingulate

08/02/2022 12:25

Feb 8 (Reuters) - Cingulate Inc  CING.O :
    * CINGULATE PROVIDES 2022 CLINICAL PLAN FOR CTX-1301, AN
INVESTIGATIONAL MEDICATION FOR ATTENTION DEFICIT/HYPERACTIVITY
DISORDER (ADHD)
    * CINGULATE INC - THIS YEAR, COMPANY PLANS TO INITIATE ITS
CTX-1301 PHASE 3 CLINICAL STUDIES

Source text for Eikon:  ID:nGNX3qY513 
Further company coverage:  CING.O 

 ((Reuters.Briefs@thomsonreuters.com;))